Focus: RadioMedix is a specialized radiopharmaceutical company focused on diagnostic imaging and therapeutic radiopharmaceuticals for oncology and nephrology. The company is publicly traded and headquartered in Houston, TX with a 20-year track record in nuclear medicine innovation.
Profile data last refreshed 14h ago · AI intelligence enriched 3w ago
RadioMedix offers specialized expertise in an emerging oncology niche but limited scale and hiring suggest this is better for niche specialists than broad-based career growth.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
ANDA-approved diagnostic radiopharmaceutical that represents the company's lead commercial product leveraging PSMA-targeting technology for oncology imaging.
Help build intelligence for RadioMedix
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from RadioMedix's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
RadioMedix wins FDA ANDA approval for Ga-68 PSMA-11 PET imaging agent - AuntMinnie
RadioMedix wins FDA ANDA approval for Ga-68 PSMA-11 PET imaging agent AuntMinnie
RadioMedix Announces Receiving FDA Approval of its Generic Ga-68 PSMA-11 Radiodiagnostic for Prostate Cancer - GlobeNewswire
RadioMedix Announces Receiving FDA Approval of its Generic Ga-68 PSMA-11 Radiodiagnostic for Prostate Cancer GlobeNewswire
RadioMedix Marks 20 Years with New Pancreatic Cancer Alpha Therapy - BriefGlance
RadioMedix Marks 20 Years with New Pancreatic Cancer Alpha Therapy BriefGlance
RadioMedix to Present at SNMMI 2026 and Mark 20 Years of Radiopharmaceutical Innovation - GlobeNewswire
RadioMedix to Present at SNMMI 2026 and Mark 20 Years of Radiopharmaceutical Innovation GlobeNewswire
One doctor helped kickstart US nuclear medicine’s new wave. Now he’s refining it. - Pharma Voice
One doctor helped kickstart US nuclear medicine’s new wave. Now he’s refining it. Pharma Voice
Radiomedix bets on alpha emitters for radiopharma’s future - BioWorld News
Radiomedix bets on alpha emitters for radiopharma’s future BioWorld News
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Toward Integrated Independence: Johannes Czernin Discusses the Future of Theranostics with Ebrahim Delpassand, Eric Rohren, and Wolfgang Weber.
Targeted α-Emitter Therapy with (212)Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo